Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group LLC in a research note issued on Thursday. They presently have a $16.00 target price on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 48.22% from the company’s current price.

Other equities analysts have also issued research reports about the company. Raymond James Financial, Inc. set a $18.00 price target on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Cantor Fitzgerald set a $32.00 price target on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 24th. Ladenburg Thalmann Financial Services set a $31.00 price target on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 24th. Wells Fargo & Company reissued an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a report on Tuesday, June 27th. Finally, BidaskClub lowered Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 6th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Bellicum Pharmaceuticals presently has an average rating of “Hold” and an average target price of $26.20.

Shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) traded up 5.21% during mid-day trading on Thursday, hitting $10.80. The stock had a trading volume of 633,419 shares. The firm’s market cap is $358.67 million. The firm has a 50 day moving average price of $9.58 and a 200 day moving average price of $11.74. Bellicum Pharmaceuticals has a 52-week low of $7.41 and a 52-week high of $23.11.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same period in the previous year, the business posted ($0.61) EPS. Equities analysts predict that Bellicum Pharmaceuticals will post ($3.02) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/14/bellicum-pharmaceuticals-inc-blcm-stock-rating-reaffirmed-by-jefferies-group-llc.html.

In other Bellicum Pharmaceuticals news, VP Ken Moseley sold 13,823 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $12.26, for a total value of $169,469.98. Following the sale, the vice president now owns 14,314 shares of the company’s stock, valued at approximately $175,489.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David M. Spencer sold 10,000 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $11.54, for a total value of $115,400.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,260 shares of company stock worth $290,048. Corporate insiders own 23.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System boosted its holdings in Bellicum Pharmaceuticals by 16.7% in the 2nd quarter. California State Teachers Retirement System now owns 48,146 shares of the biopharmaceutical company’s stock valued at $562,000 after purchasing an additional 6,900 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Bellicum Pharmaceuticals by 26.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,319 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 4,684 shares in the last quarter. State Street Corp boosted its holdings in Bellicum Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock valued at $4,872,000 after purchasing an additional 59,321 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Bellicum Pharmaceuticals by 223.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock valued at $1,612,000 after purchasing an additional 95,336 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new stake in Bellicum Pharmaceuticals in the 2nd quarter valued at approximately $448,000. 55.73% of the stock is currently owned by institutional investors.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.